Pevonedistat and azacitidine upregulate NOXA ( PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemiaPevonedistat and azacitidine upregulate NOXA ( PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
Dysregulation of apoptotic equipment is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival benefit. B-cell lymphoma protein-2 (BCL2) overexpression is a typical characteristic in hematologic malignancies.